Research
Hormonal
Antibiotic treatment (specifically norfloxacin and ampicillin) improves fasting blood glucose and oral glucose tolerance in obese, insulin-resistant mice by reducing plasma LPS levels and intestinal inflammation.
While antibiotics can improve glucose metrics in animal models by reducing gut inflammation, they are not a recommended treatment for humans due to side effects like weight gain. Focus on safer microbiota modulation through diet and probiotics instead.
LimitedSupportsLOW confidence
Treatment with norfloxacin and ampicillin (1 g/L each) for 2 wk, suppressed the numbers of cecal bacteria in ob/ob mice. The treated animals displayed a significant improvement in fasting blood glucose and oral glucose tolerance.
Why this rating
Based on animal studies; human application is cautioned against due to side effects like weight gain.
Source
Intestinal microbiota and type 2 diabetes: From mechanism insights to therapeutic perspective
Jun-Ling Han et al. · World Journal of Gastroenterology · 2014
DOI 10.3748/wjg.v20.i47.17737
narrative_reviewCited 178×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Modulating gut microbiota using probiotics, prebiotics, antibiotics, or fecal microbiota transplantation improves glucose metabolism and insulin resistance in type 2 diabetes.Moderate
- Fecal microbiota transplantation (FMT) from lean donors improves peripheral and hepatic insulin sensitivity in patients with metabolic syndrome.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →